Skip to main content
. 2019 Jun 6;34(4):153–160. doi: 10.1097/YIC.0000000000000271

Table 2.

Summary of treatment emergent adverse events, and treatment emergent adverse events with an incidence of ≥5% in either treatment group in the 2-week treatment period

graphic file with name icp-34-153-g005.jpg